Scout Venture Partners
Holly is the founder of Scout Venture Partners, providing a range of services to early-stage life science companies as well as leading venture investment firms with a focus on medical devices and specialty pharmaceuticals. During her venture career, Holly has been involved in a broad range of successful life science companies, including Nanostream, NuVasive, Northstar Neuroscience, Orquis Medical, Pharmion, and Xcel Pharmaceuticals. She has been involved in venture investments totaling over $100 million of equity capital, including two of the largest medical device venture deals ever completed.
Previously, Holly was a Vice President at AEA Investors in New York City, where she led both growth equity and buyout investment for prospective life science companies. Her responsibilities at AEA included building the life science practice within the firm; screening and sourcing potential investment opportunities; negotiating and managing various aspects of the due diligence process; and working closely with management teams as an active board participant. Prior to AEA, Holly was a Kauffman Fellow at Domain Associates, a venture capital firm focused on early stage life science investments. Her previous experience includes working as an investment analyst at Apax Partners (formerly Patricof & Co.) as a member of the healthcare team and also as a financial analyst at Morgan Stanley.
Education, Personal, and Fellowship
Holly received an AB in economics and international commerce from Brown University, where she was a four-year varsity soccer player. She has an MBA in healthcare systems and entrepreneurial management from the Wharton School, where she was awarded a Kaiser Foundation scholarship. She is the recent mother of a boy, Tyler Sisitsky.
Holly Hagens is a member of Kauffman Fellows Class 5 and served her fellowship under mentor Brian Dovey at Domain Associates in Princeton, New Jersey.